Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.
Reference tool — not medical advice. A deterministic aid modelling the AASLD/IDSA + CASL simplified hepatitis C treatment algorithm (Health Canada lens). It does not prescribe; clinician judgement, current product monographs, drug–drug interaction screening, and live public coverage are always required. Runs entirely in your browser — no data is collected.

Evidence: Direct-acting antivirals for HCV have been universally co… 2018 · sources last checked 2026-07-22

Hepatitis C treatment selector

Enter the HCV genotype and liver status to get the ranked pan-genotypic direct-acting antiviral (DAA) regimens of the simplified treatment pathway — with the guideline reasoning and references behind each. Specialist and salvage situations are flagged for referral, not modelled in depth.

Guideline lens

CASL/AMMI Canada — Management of chronic HCV / CanHepC simplified algorithm 2024 link
Coverage: All three regimens are Health Canada-approved and, since 2018, DAAs have been universally covered by provincial/territorial public drug plans across Canada — confirm the patient’s live plan and any prior-authorization criteria.[5]

Patient characteristics

HCV genotype

Liver status

Refer-out / specialist flags

Any one of these takes the patient off the simplified pathway → refer.

Select the genotype and liver status to begin.

e.g. Genotype 3 + No cirrhosis, or set a Prior treatment / Decompensated cirrhosis flag to see the referral pathway.

References

  1. [1]AASLD-IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. link
  2. [2]AASLD-IDSA. Simplified HCV Treatment for Treatment-Naive Adults Without Cirrhosis / With Compensated Cirrhosis. link
  3. [3]CASL/AMMI Canada & CanHepC — Management of chronic hepatitis C: Canadian guidance / simplified algorithm (Canadian Liver Journal). link
  4. [4]Health Canada — Drug Product Database & product monographs (Maviret [glecaprevir/pibrentasvir], Epclusa [sofosbuvir/velpatasvir], Vosevi [sofosbuvir/velpatasvir/voxilaprevir]). link
  5. [5]Direct-acting antivirals for HCV have been universally covered by provincial/territorial public drug plans across Canada since 2018 (Public Health Agency of Canada / provincial formularies — confirm live). link
  6. Guidelines:CASL/AMMI Canada — Management of chronic HCV / CanHepC simplified algorithm (2024) · AASLD-IDSA HCV Guidance: Simplified Treatment (2024)